bioscienc momentum stabl pdfviii continu
drag profil updat sinc analyst day
increment margin like weaken though
perceiv option ambar
underli result estim underli ep miss adjust
one-tim item grifol report revenu vs mse
fx pt larger headwind model organ growth
pt estim reflect pt underli momentum
acceler gross margin line estim opex disciplin
drove oper margin bp estim ep vs
mse includ non-op benefit tigenix divestitur
exclud ep would vs mse pleas see exhibit
reconcili result vs mse
bioscienc momentum stabl underli market trend unchang
analyst day bioscienc organ growth came pt
estim reflect sequenti comp-adjust stabil commentari end
market similar analyst day almost two month ago
bioscienc profil could come high-singl digit hsd growth albumin
ivig inclus price tailwind estim bp
quarter pdfviii outlook continu pressur saw double-digit
dd declin quarter like pt drag bioscienc growth similar
last quarter hemlibra roch tender price effect continu weigh
market howev given saw difficult price comp given
suppli issu market like could see greater price
tailwind perhap pt though balanc pdfviii declin
rais bioscienc estim pt embed pt momentum
deceler acknowledg degre price creat
greater tailwind underli trend remain stabl could prove
conserv updat pipelin sinc analyst day
ambar track data readout grifol scig offer expect
launch us
diagnost hospit growth modestli expect
busi still acceler diagnost growth hospit organ
growth expect growth respect
sequenti comp-adjust basi segment acceler pt
pt respect diagnost pipelin continu robust near
term catalyst includ uptak new procleix panther diagnost test
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
continu traction erytra eflexi iv solut standout
hospit divis driven salin us hospit smaller
divis revenu base enthusiasm analyst day see
like focu tuck-in acquisit
flexibl margin stori take prudent
approach discuss follow analyst day grifol indic
inorgan center addit haema june ibbi would like
margin accret year third parti contract expir gross
margin like pressur result haema center
addit main driver margin perform margin
dilut haema center like drag gross margin
potenti price tailwind bioscienc level
invest opex spend grifol decid make plasma collect
apparatu depend market dynam compani control opex
given lower gross margin acknowledg option latter
two provid margin taken prudent approach sinc
see visibl first item model oper margin
bp y/i
remain rel underweight limit margin expans updat
compani busi profil pipelin increment versu analyst day
june see thesis-alt item quarter continu
see stronger case top-line growth margin expans latter
drive rel underweight rate maintain price target
reflect multipl ep turn premium eu pharma
line histor trend convert price target usd
assum adr discount line histor averag reach
bioscienc deceler margin flat
bioscienc deceler margin flat
price target adr assum class share
trade one year forward earn turn premium
european pharma ii adr trade discount
class share consist averag valuat spread
new plasma bull market bioscienc growth push doubl digit
high singl digit sustain strong result albumin
bolster rebound ivig ebitda margin exceed valuat gap
close
growth leverag upsid remain constrain pipelin catalyst
scarc plasma growth remain slightli industri rate diagnost limit
growth profil underli margin remain pressur major
pipelin catalyst ambar materi
bioscienc growth slow sustain market pressur factor viii renew
competit larger incumb smaller player keep plasma
growth rate low singl digit slower growth price pressur
busi hamper overal growth valuat spread widen
underweight rate driven
combin limit upsid catalyst
margin pressur competit threat
bioscienc busi less upsid
versu rest coverag
see fewer opportun non-
oper upsid rel prior histori
believ margin y/i
bear case scenario scig cidp
rabi play plasma growth could push
low end mid singl digit
upsid pipelin catalyst scarc
prospect alzheim success low
key data event year away
ebit margin
everi bp ebit margin translat
ep
bioscienc growth growth grifol
bioscienc divis account
revenu key driver perform
assum spread remain around long
term averag
risk achiev price
narrow valuat spread adr vs
upsid estim
stabil competit situat us ivig
could support favor price trend
million except ep
euro million except per share data
good sold
share income/loss equiti account investe
net incom attribut common
loss attribut non-control interest
euro million except per share data
euro million except per share data
cash equival
trade receiv
properti plant equip net
goodwil intang asset
invest equiti account investe
debt associ
profit attribut parent
equiti attribut parent
euro million except per share data
profit tax
adjust
amort depreci
chang oper work capit
cash flow use oper activ
payment invest
group compani busi unit
properti plant equip intang asset
properti plant equip
proce sale properti plant equip
invest activ
proce payment equiti instrument
acquisit treasuri stock
dispos treasuri stock
redempt repay
proce payment financi liabil intrument
dividend interest equiti instrument paid receiv
payment financ activ
financ activ
effect exchang rate chang
begin period
end period
